Correlation analysis between EGFR gene mutation status, ALK positivity and demographic data, tumor biomarkers, radiological and pathological features in patients with lung adenocarcinoma

肺腺癌患者EGFR基因突变状态、ALK阳性与人口统计学数据、肿瘤生物标志物、放射学和病理学特征的相关性分析

阅读:1

Abstract

OBJECTIVE: This study aimed to explore the relationship between EGFR mutations, ALK positivity, and demographic, tumor, radiological, and pathological characteristics in lung adenocarcinoma patients. METHODS: This study included 626 patients with early-stage lung adenocarcinoma who underwent surgical resection between October 2017 and December 2023.EGFR and ALK mutations were analyzed postoperatively. Clinical, pathological, and imaging features such as gender, age, smoking status, and tumor characteristics were assessed. Patients were categorized based on their mutation status, and comparisons were made regarding their clinical and imaging features. RESULTS: Results indicated that EGFR-positive patients were predominantly female, younger, and had a higher frequency of non-smokers compared to the wild-type (WT) group. EGFR mutations, particularly the exon 19 deletions and L858R mutations, were more common in patients with moderate differentiation and lepidic or acinar predominant histological subtypes. CT imaging revealed that EGFR-positive tumors were smaller in size and had fewer solid components compared to WT tumors. Additionally, certain CT features such as the spicule sign and air bronchogram were significantly associated with EGFR mutations. For ALK mutations, the analysis showed that patients with ALK-positive tumors had distinct radiological features, including a higher occurrence in the lower lobes and fewer ground glass nodules compared to the WT group. CONCLUSIONS: The study concluded that specific radiological and pathological characteristics, along with EGFR and ALK mutation statuses, could be used to guide the treatment and diagnosis of lung adenocarcinoma.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。